-logo-1200x675.png?v=20261007110104)
What happened
Procter & Gamble Co. (NYSE: PG) CEO Shailesh Jejurikar sold about $5.71 million of stock without reducing his existing direct common-share count. An equal-sized option exercise supplied the shares he sold.
Jejurikar exercised options for 35,000 shares at $78.52 each on October 23, then sold 35,000 shares at a weighted average $163.0871. The transactions were reported in an SEC Form 4 filed October 26.
His direct holding ended at about 55,391 shares, matching its level before the exercise. His remaining options declined, so an unchanged common-share count does not mean his overall equity exposure stayed unchanged.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Shares exercised and then sold | 35,000 shares | SEC Form 4 | |
| Exercise price per share | $78.52 | SEC Form 4 | |
| Weighted average sale price | $163.0871 | SEC Form 4 | |
| Direct shares before exercise and after sale | 55,390.9973 shares | No net change across both transactions | Calculated from SEC Form 4 |
| Gross sale proceeds less exercise cost | about $2.96 million before taxes and transaction costs | Calculated from SEC Form 4 |
Read more: Procter & Gamble (PG) stock analysis and investment case
Why it matters
The sequence explains why a sale percentage can mislead. The exercise first increased the direct balance to about 90,391 shares. The sale then brought it back to about 55,391.
Dividing the shares sold by that temporary, post-exercise balance produces 38.7%. That figure does not measure a reduction from his direct holding before the day's transactions.
The option exercise cost $2,748,200 at the reported price. The sale produced approximately $5,708,049, leaving a spread of about $2.96 million before taxes and transaction costs.
That spread is not the same as take-home proceeds. The filing does not provide the tax bill or transaction costs needed to calculate that amount.
Jejurikar retained 70,170 options from the reported grant, with a $78.52 exercise price and a February 28, 2028 expiration. The form also reports separate indirect holdings through trusts and a retirement-plan trustee.
Stock perps: every US stock that trades as a perpetual future, by leverage, live
What's next
Later filings can show whether another sale is paired with an exercise or reduces the existing direct holding. The comparison needs both transactions, plus any changes in options and indirect ownership.
The current filing documents an exercise and sale. It does not disclose a reason for the decision or forecast the company's operating performance.
Correction, October 26, 2026: The earlier headline emphasized a 38.7% sale using the balance after an option exercise. The complete exercise-and-sale sequence left the direct common-share count unchanged. Options held declined.
More from OptimistFi
- PG stock: the Procter & Gamble thesis, its status and the next test to watch
- Stock research on every company OptimistFi covers
From OptimistFi Perps
- Top perps movers today: stocks, commodities, FX and indices
- Open interest live: crypto and stock perps by exchange
- All perp markets: price, open interest and funding by venue
- Futures calculator: liquidation price, PnL and fees by exchange
- Perp funding rates live: what longs and shorts pay on every venue
Sources
- SEC Form 4, Shailesh Jejurikar, Procter & Gamble Co — Statement of changes in beneficial ownership covering the Oct. 23, 2026 option exercise and share sale, signed Oct. 26, 2026
Read the full OptimistFi thesis on Procter & Gamble Co: https://optimistfi.com/stocks/PG
See what would break the Procter & Gamble Co thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full Procter & Gamble Co investment case, its status and the next test to watch live on the Procter & Gamble Co thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
